EpiCept Corporation (NASDAQ: EPCT), a specialty pharmaceutical company, is focused on meeting unmet medical needs in cancer treatment and pain management. The company has approval from the European Commission to use Ceplene for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Additionally, EpiCept is utilizing its biopharmaceutical discovery capabilities for the discovery and advancement of apoptosis inducers. For further information, visit the Company’s web site at www.epicept.com.
- 18 years ago
QualityStocks
EpiCept Corporation (NASDAQ: EPCT)
Tags Rodman & Renshaw
Related Post
-
Greenland Mines Ltd. (NASDAQ: GRML) Advances World-Class Palladium Deposit with Major Resource Upgrade
The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian…
-
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Is Building a Modern Public Safety Platform by Integrating Tools, Training and Policy
Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools,…